Story perspectives

Study: GLP-1 Breaks Increase Heart Risks for Diabetic Veterans

4/2/2026

Center

Veterans' Diabetes Risks

A recent study tracked over 333,000 U.S. veterans with type 2 diabetes and found a six-month GLP-1 break raises risk of heart attack, stroke, and death by 22%.
GLP-1 drugs such as semaglutide and tirzepatide reduced cardiovascular events by 18% with continuous use.
Interruptions diminished these benefits and underscored the need for ongoing treatment.
Experts say cost and side effects must be addressed to help patients stay on therapy.

Right

Microdosing Controversy Explored

GLP-1 receptor agonists have sparked debate over microdosing for weight loss.
Advocates, including Dr. Terry Dubrow, promote low daily doses and benefits for people without obesity.
Influencers, including venture capitalist Bryan Johnson, promote microdosing as a longevity strategy.
Dr. Andre Teixeira notes microdosing may be less effective and more costly.
A doctor warns that self-microdosing can cause frustration and side effects and underscores the need to consult healthcare providers.

1 of 2

Veterans' Diabetes Risks

A recent study tracked over 333,000 U.S. veterans with type 2 diabetes and found a six-month GLP-1 break raises risk of heart attack, stroke, and death by 22%.
GLP-1 drugs such as semaglutide and tirzepatide reduced cardiovascular events by 18% with continuous use.
Interruptions diminished these benefits and underscored the need for ongoing treatment.
Experts say cost and side effects must be addressed to help patients stay on therapy.

1 / 2